WELLDOC INC

Welldoc Receives FDA Clearance for Long-Acting Insulin Support for Award-Winning Digital Health Solution BlueStar®

Retrieved on: 
Wednesday, June 3, 2020
Endocrine system, Eli Lilly and Company, Medicine, Endocrinology, Diabetes, Peptide hormones, Recombinant proteins, Insulin, RTT, Medical device, Basal

The Insulin Adjustment Program (IAP), supports the process of basal insulin titration by health care providers for adults with type 2 diabetes.

Key Points: 
  • The Insulin Adjustment Program (IAP), supports the process of basal insulin titration by health care providers for adults with type 2 diabetes.
  • Patients who are prescribed IAP as part of BlueStar, will benefit from the ease of real time adjustments to their insulin.
  • BlueStar is the only FDA approved and reimbursable Software as a Medical Device that works with a patient's existing devices.
  • BlueStar, the first FDA-cleared digital health solution, guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their conditions and enhancing connections to their health care team.

Welldoc Announces Collaboration with Dexcom to Enhance the Value of BlueStar® with the Dexcom G6® CGM System

Retrieved on: 
Wednesday, March 11, 2020
Medicine, Dexcom, Organ systems, Clinical medicine, Diabetes

Welldoc and Dexcom signed an initial data partnership in 2019.This new collaboration will allow Welldoc's award-winning BlueStar, a digital health product for individuals living with type 1 and type 2 diabetes, to deliver insights to Dexcom G6 CGM system users.

Key Points: 
  • Welldoc and Dexcom signed an initial data partnership in 2019.This new collaboration will allow Welldoc's award-winning BlueStar, a digital health product for individuals living with type 1 and type 2 diabetes, to deliver insights to Dexcom G6 CGM system users.
  • The parties will also explore additional opportunities with Welldoc customers to leverage a more integrated offering.
  • "This partnership is a significant milestone for Dexcom, Welldoc, healthcare providers, and most importantly for those living with diabetes.
  • BlueStar was the first FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes.

Competitive Health Partners with Welldoc to Offer Digital Health Tool to Employers to Manage Their Type 2 Diabetes

Retrieved on: 
Thursday, October 31, 2019
Health, Organ systems, RTT, Diabetes, Blue star, Bluestar, Food and Drug Administration, Medicine

IRVINE, Calif. and COLUMBIA, Md., Oct. 31, 2019 /PRNewswire/ -- Competitive Health and Welldoc announced today a partnership that will offer Competitive Health's clients BlueStar, Welldoc's digital assistant for individuals living with type 2 diabetes.

Key Points: 
  • IRVINE, Calif. and COLUMBIA, Md., Oct. 31, 2019 /PRNewswire/ -- Competitive Health and Welldoc announced today a partnership that will offer Competitive Health's clients BlueStar, Welldoc's digital assistant for individuals living with type 2 diabetes.
  • "Welldoc's BlueStar mobile health solution is utilized by some of the largest companies in the United States to help control diabetes; Competitive Health can now deliver an award-winning chronic care digital health solution through its wholesaler partners to employers," said Kim Darling, Competitive Health CEO & Founder.
  • BlueStar, the FDA-cleared digital health app engages people with type 2 diabetes and delivers precision, real-time feedback to help improve long-term health.
  • BlueStar was the first FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes.